Arete initiated coverage on Nebius Group N.V. with a new price target
$NBIS
Computer Software: Programming Data Processing
Technology
Arete initiated coverage of Nebius Group N.V. with a rating of Buy and set a new price target of $84.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/14/2025 | $68.00 | Buy | Goldman |
| 6/5/2025 | $84.00 | Buy | Arete |
| 5/6/2025 | $34.00 | Outperform | Northland Capital |
| 2/25/2025 | $50.00 | Buy | DA Davidson |
| 2/24/2025 | $51.00 → $60.00 | Buy | BWS Financial |
| 1/13/2025 | $51.00 | Buy | BWS Financial |
FWP - Nebius Group N.V. (0001513845) (Subject)
FWP - Nebius Group N.V. (0001513845) (Subject)
FWP - Nebius Group N.V. (0001513845) (Subject)
Goldman initiated coverage of Nebius Group N.V. with a rating of Buy and set a new price target of $68.00
Arete initiated coverage of Nebius Group N.V. with a rating of Buy and set a new price target of $84.00
Northland Capital initiated coverage of Nebius Group N.V. with a rating of Outperform and set a new price target of $34.00
MarketNewsUpdates News Commentary NEW YORK, Sept. 11, 2025 /PRNewswire/ -- The global Diagnostic Biomarker market is experiencing unprecedented growth and is projected to continue to see substantial growth in years to come. A recent report from the (NIH) National Library of Medicine discussed the AI-Assisted Biomarker, said that: "Recently, advancements in healthcare digitization and personalized treatments have led to groundbreaking developments. Utilization of AI and ML has the potential to enhance comprehension of disease onset and progression, potentially uncovering new disease subtypes, unveiling novel drug targets, advancing the field of precision medicine, propelling efforts towards d
Nebius Group N.V. (("Nebius Group" or the "Company", NASDAQ:NBIS), a leading AI infrastructure company, today announced the pricing of its offering of $2.75 billion aggregate original principal amount of convertible senior notes, in two series: $1,375,000,000 aggregate original principal amount of 1.00% convertible notes due 2030 (the "2030 Notes") and $1,375,000,000 aggregate original principal amount of 2.75% convertible notes due 2032 (the "2032 Notes", and together with the 2030 Notes, the "Notes"), in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering was upsized from the previousl
Nebius Group N.V. (("Nebius Group" or the "Company", NASDAQ:NBIS), a leading AI infrastructure company, today announced the pricing of its previously announced underwritten public offering of $1 billion of the Company's Class A ordinary shares at a public offering price of $92.50 per Class A ordinary share. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional $150 million of Class A ordinary shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on September 15, 2025, subject to customary closing conditions. Goldman Sachs & Co. LLC is acting as lead book-running manager for the pr
Nebius (NASDAQ:NBIS), a leading AI infrastructure company, today announced the appointment of Marc Boroditsky as Chief Revenue Officer as the company continues to build out its global sales team. A seasoned senior tech executive, Marc has a strong global go-to-market track record of driving high growth – in five years at Twilio he grew paying customers six times, and revenue more than 10 times to $4 billion. Previously he founded several successful companies, and served as a senior leader at Oracle and most recently Cloudflare. Arkady Volozh, founder and CEO of Nebius, welcomed Marc to the company: "We are building a global company and planning to grow many times in the coming years.
MarketNewsUpdates News Commentary NEW YORK, Sept. 11, 2025 /PRNewswire/ -- The global Diagnostic Biomarker market is experiencing unprecedented growth and is projected to continue to see substantial growth in years to come. A recent report from the (NIH) National Library of Medicine discussed the AI-Assisted Biomarker, said that: "Recently, advancements in healthcare digitization and personalized treatments have led to groundbreaking developments. Utilization of AI and ML has the potential to enhance comprehension of disease onset and progression, potentially uncovering new disease subtypes, unveiling novel drug targets, advancing the field of precision medicine, propelling efforts towards d
Annualized run-rate revenue(1) (ARR) guidance increased to $900 million to $1.1 billion for the end of 2025 Revenue for Q2 of $105.1 million, up 625% year-on-year and 106% quarter-on-quarter Core business achieves positive Adjusted EBITDA ahead of plan In the process of securing more than 1 GW of power by the end of 2026 Nebius Group N.V. (NASDAQ:NBIS), a leading AI infrastructure company, today announced its unaudited financial results for the second quarter ended June 30, 2025. "Nebius is continuing to deliver exceptional results," said founder and CEO Arkady Volozh. "In Q2 we more than doubled revenue from the previous quarter, and our core business achieved positive Adjus
SC 13G/A - Nebius Group N.V. (0001513845) (Subject)